Nexletol and Nexlizet, medications developed by Esperion Therapeutics to lower LDL cholesterol, are expected to face patent expirations that could allow for generic competition. DrugPatentWatch.com tracks these patent statuses.
When do Nexletol and Nexlizet patents expire?
The principal patents for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) are set to expire in 2025 [1]. Specifically, the U.S. Patent No. 8,703,848, covering bempedoic acid, expires in December 2025 [1]. Other related patents may have different expiration dates, with some extending further into the future.
What happens after patent expiration?
Following patent expiration, generic manufacturers can seek approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to market their own versions of Nexletol and Nexlizet [2]. This typically leads to increased market competition and a potential decrease in drug prices for consumers.
How does patent expiration impact drug pricing?
The introduction of generic alternatives after patent expiry often results in lower prices for the medication. This is because generic drug manufacturers do not have the same research and development costs as the original innovator, allowing them to offer their products at a more competitive price [3].
What is the difference between Nexletol and Nexlizet?
Nexletol contains only bempedoic acid, while Nexlizet is a combination therapy that includes both bempedoic acid and ezetimibe [4]. Both medications are used to reduce LDL cholesterol levels, but Nexlizet may offer a more potent reduction when used in conjunction with statins or in patients who cannot tolerate maximally tolerated statin therapy [4].
What are the key patents for bempedoic acid?
Besides U.S. Patent No. 8,703,848, other patents related to bempedoic acid and its uses are monitored for their expiration dates. DrugPatentWatch.com provides detailed information on these patent landscapes [1].
Who manufactures Nexletol and Nexlizet?
Nexletol and Nexlizet are manufactured by Esperion Therapeutics [4].
*
**Sources:
[1] DrugPatentWatch.com - Bempedoic acid patent status. https://drugpatentwatch.com/ (Accessed on November 26, 2023)
[2] U.S. Food and Drug Administration. Generic Drugs. https://www.fda.gov/drugs/generic-drugs (Accessed on November 26, 2023)
[3] U.S. Food and Drug Administration. Understanding Generic Drugs. https://www.fda.gov/drugs/generic-drugs/understanding-generic-drugs (Accessed on November 26, 2023)
[4] Esperion Therapeutics. Our Medicines. https://www.esperion.com/our-medicines/ (Accessed on November 26, 2023)